Bharat Serums Gets CDSCO Panel Nod for Phase III Trial of IVIG in Chronic ITP

Medically Reviewed By : Dr. Kamal Kant Kohli

Published On 2025-06-26 14:27 GMT | Update On 2025-06-26 14:27 GMT

New Delhi: Bharat Serums and Vaccines has received approval from the Subject Expert Committee (SEC) functional under the Central Drugs Standard Control Organisation (CDSCO) to conduct a Phase III clinical trial of Human Normal Immunoglobulin for Intravenous Use (IVIG) 5% Solution.

This came after the firm presented the revised protocol — updated as per the recommendations given by the committee during the SEC meeting held on February 11, 2025 — for the proposed Phase III clinical trial titled:

“An Open-Label, Multicenter, Phase III Clinical Study in India to Evaluate the Efficacy and Safety of Human Normal Immunoglobulin for Intravenous Use (IVIG) in Chronic Immune Thrombocytopenia (ITP)”, vide Protocol No. BSV_IVIG_ITP_2023_02, Version 4.0, dated April 17, 2025.

Human Normal Immunoglobulin for Intravenous Use (IVIG) 5% solution is a plasma-derived product containing primarily IgG antibodies, used to enhance immunity in individuals with immune deficiencies or autoimmune disorders. Administered intravenously, it helps the body fight infections and regulate immune responses.

At the recent SEC (Hematology) meeting held on June 10, 2025, the expert panel reviewed the revised protocol and, after detailed deliberation, “recommended the grant of permission to conduct the Phase III clinical trial as per revised Protocol No. BSV_IVIG_ITP_2023_02, Version 4.0 dated 17.04.2025.”

Also Read: Sun Pharma Gets Relief on Packaging Norms for Pantoprazole-Levosulpiride FDC

Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.

NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.

Dr. Divya Colin

Dr. Divya Colin, a Doctor of Pharmacy Graduate with extensive experience in clinical and hospital settings and confidently equipped with diagnostic and therapeutic skills. She also has spread out exposure to Oncology Departments in Mysore Medical College and Research Institute as Oncology Pharmacist. Currently she is building a career in clinical research and clinical data management. She has been a part of Medical Dialogue since January 2022.

Comments Policy

Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .

Bharat Serums Gets CDSCO Panel Nod for Phase III Trial of IVIG in Chronic ITP

Similar News

Sun Pharma Told to Limit Phase III Revefenacin Study to Triple Therapy COPD Patients

Box Warning, Dose Limits: India Set To Tighten Nimesulide Use

CDSCO, ICMR Release Standard Evaluation Protocols for Diagnostic Kits in India

Lupin Secures CDSCO Panel Clearance for Phase III COPD Inhaler Trial

CDSCO Cancels Registration Certificate of G3 Medical Systems for Import of Allergan Cosmetics

Lupin Secures CDSCO Panel Nod for Phase IV Trial of Budesonide-Based COPD Inhaler

CDSCO Launches Separate Online Provision for Subsequent Importers of Medical Devices, IVDs

Cocrystals of Approved APIs to Be Treated as New Drugs, Clarifies CDSCO